Current uses of dietary therapy for patients with far-advanced CKD
Stakeholders Interviewed Primary interviews for this study involved: Manufacturers and suppliers in the market value chain Distributors, channel partners, and integrators End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market) Industry experts, technology specialists, consultants, and regulatory professionals Senior executives (CEOs, CTOs, VPs, Directors) and product managers Interview Process Interviews were conducted via: Structured and semi-structured questionnaires Telephonic and video interactions Email correspondences Expert consultation sessions Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation
Besides, our study was neither randomized nor blinded, leading to potential bias, whose influence should be mitigated by matching for relevant confounders
The bones: Hidden risks Bone is metabolically active and responds to incretin hormones, like GLP-1 and GIP, released in the intestines after eating to stimulate the pancreas to produce insulin
Join the waitlist and be first in line when we open
Retatrutide targets three receptors
